All AbMole products are for research use only, cannot be used for human consumption.
Lumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1.
MedComm (2020). 2023 Sep 20;4(5):e363.
Arachidonic acid metabolism in health and disease
Lumiracoxib purchased from AbMole
| Molecular Weight | 293.72 |
| Formula | C15H13ClFNO2 |
| CAS Number | 220991-20-8 |
| Solubility (25°C) | DMSO 40 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Bernard Bannwarth, et al. Lumiracoxib in the management of osteoarthritis and acute pain
| Related COX Products |
|---|
| Firocoxib
Firocoxib is a selective COX-2 inhibitor exhibiting high selectivity to inhibit COX-2. |
| Celecoxib
Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor (IC50 values are 15 and 0.04 μM for COX-1 and COX-2 respectively). |
| Nepafenac
Nepafenac is an analgesic selective inhibitor of COX-2. |
| Ampiroxicam
Ampiroxicam is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory compound. |
| Bromfenac Sodium
Bromfenac is a nonsteroidal anti-inflammatory compound (NSAID), which has anti-inflammatory activity and may block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
